NCT07437079

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	NNC6989-0001 A	Participants assigned to the active intervention receive NNC6989-0001 A
DRUG	Placebo (NNC6989-0001 A)	Participants assigned to the placebo, receive placebo matched in appearance to the active drug.

Timeline

• Start date: 2026-02-24
• Primary completion: 2027-01-21
• Completion: 2027-01-21
• First posted: 2026-02-27
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study